Clark, M;
Cooper, S;
Naughton, F;
Ussher, MH;
Emery, J;
McDaid, L;
Thomson, R;
Phillips, L;
Bauld, L;
Aveyard, P;
et al.
Clark, M; Cooper, S; Naughton, F; Ussher, MH; Emery, J; McDaid, L; Thomson, R; Phillips, L; Bauld, L; Aveyard, P; Torgerson, D; Berlin, I; Lewis, S; Parrott, S; Hewitt, C; Welch, C; Parkinson, G; Dickinson, A; Sutton, S; Brimicombe, J; Bowker, K; McEwen, A; Vedhara, K; Coleman, T
(2024)
Smoking, nicotine and pregnancy 2 (SNAP2) trial: protocol for a randomised controlled trial of an intervention to improve adherence to nicotine replacement therapy in pregnancy.
BMJ Open.
ISSN 2044-6055
(In Press)
SGUL Authors: Ussher, Michael Henry
|
Microsoft Word (.docx)
Accepted Version
Restricted to Repository staff only until 30 May 2025.
Download (186kB)
|
Abstract
Introduction: Smoking in pregnancy is harmful for unborn babies, infants, and women. Nicotine replacement therapy (NRT) is offered as usual stop smoking support in the UK. However, this is often used in insufficient doses, intermittently, or for too short a time to be effective. This randomised controlled trial (RCT) explores whether a bespoke intervention, delivered in pregnancy, improves adherence to NRT and is effective and cost effective for promoting smoking cessation.
Methods and analysis: A two-arm parallel-group RCT for pregnant women aged ≥ 16 years and who smoke ≥1 daily cigarette (pre-pregnancy smoked ≥5), and who agree to use NRT in a quit attempt. Recruitment is from antenatal care settings and via social media adverts. Participants are randomised using blocked randomisation with varying block sizes, stratified by gestational age (<14 weeks or ≥14 weeks) to receive: i) usual care stop smoking support (UC) or ii) UC plus an intervention to increase adherence to NRT, called “Baby, Me and NRT”, comprising adherence counselling, automated tailored text messages, a leaflet and website.
The primary outcome is biochemically validated smoking abstinence at or around childbirth, measured from 36 weeks gestation. Secondary outcomes include NRT adherence; other smoking measures; and birth outcomes. Questionnaires collect follow up data which are augmented by medical records information. We anticipate quit rates of 10% and 16% in control and intervention groups respectively (RR = 1.6). By recruiting 1320 participants the trial should have 90% power (alpha = 5%) to detect this intervention effect. An economic analysis will use the Economics of Smoking in Pregnancy (ESIP) model to determine cost-effectiveness.
Ethics and dissemination: Ethics approval was granted by Bloomsbury NHS Research Ethics Committee (21/LO/0123). Written informed consent will be obtained from all participants. Findings will be disseminated to the public, funders, relevant practice / policy representatives, researchers, and participants.
Trial registration: ISRCTN16830506
Protocol version 5.0, 10 Oct 2023
Statistics
Item downloaded times since 01 May 2024.
Actions (login required)
|
Edit Item |